Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 1994 August; 94(2): 472–480.
PMCID: PMC295107

Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.


Because fibrin is commonly observed within arthritic joints, studies were undertaken to determine whether purified coagulation and fibrinolytic proteases degrade cartilage in vitro and to seek evidence for the activation of coagulation in arthritic joints through measurements of the levels of inhibitor-enzyme complexes and several other proteins associated with coagulation and fibrinolysis. The concentrations of 13 plasma proteins and complexes of thrombin and Factor Xa with antithrombin III were measured in synovial fluids recovered at the time of knee replacement surgery. All zymogens necessary to constitute the coagulation cascade were present. Thrombin and the combination of prothrombin plus prothrombinase induced proteoglycan release from both normal and arthritic cartilages. Factor Xa and plasmin induced release from diseased cartilage only, and urokinase, tissue plasminogen activator, and activated protein C were without effect at the levels used. At saturating levels of thrombin (> or = 2.0 microM) 80% of the proteoglycan content of normal cartilage was released within 24 h. Thrombin, which is cationic, reversibly binds cartilage with Kd = 7.0 +/- 1.0 microM and Bmax = 820 +/- 70 ng/mg of human cartilage. Levels of thrombin-antithrombin III complexes in synovial fluids and arthritis were 4-fold higher in osteo (OA) and 43-fold higher in rheumatoid (RA) than in controls (0.98 nM). Factor Xa-antithrombin III complex levels were threefold lower in OA and fivefold higher in RA than in controls (0.24 nM). These elevated levels of enzyme-inhibitor complexes imply a history of activation of coagulation within the joint, especially in RA. Since thrombin degrades cartilage in vitro and had been generated in vivo, as inferred by the existence of thrombin-antithrombin III complexes, intraarticular activation of coagulation may both contribute to the pathology of arthritis and comprise a target for therapy and diagnosis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Cooke TD, Scudamore RA. Studies in the pathogenesis of rheumatoid arthritis. 1: Immunogenetic associations. Br J Rheumatol. 1989 Jun;28(3):243–250. [PubMed]
  • Murphy G, Docherty AJ, Hembry RM, Reynolds JJ. Metalloproteinases and tissue damage. Br J Rheumatol. 1991;30 (Suppl 1):25–31. [PubMed]
  • Vaes G. Cell-to-cell interactions in the secretion of enzymes of connective tissue breakdown, collagenase and proteoglycan-degrading neutral proteases. A review. Agents Actions. 1980 Dec;10(6):474–485. [PubMed]
  • Gavrilovic J, Hembry RM, Reynolds JJ, Murphy G. Tissue inhibitor of metalloproteinases (TIMP) regulates extracellular type I collagen degradation by chondrocytes and endothelial cells. J Cell Sci. 1987 Mar;87(Pt 2):357–362. [PubMed]
  • Shinmei M, Masuda K, Kikuchi T, Shimomura Y. Interleukin 1, tumor necrosis factor, and interleukin 6 as mediators of cartilage destruction. Semin Arthritis Rheum. 1989 Feb;18(3 Suppl 1):27–32. [PubMed]
  • Cush JJ, Lipsky PE. Cellular basis for rheumatoid inflammation. Clin Orthop Relat Res. 1991 Apr;(265):9–22. [PubMed]
  • Virca GD, Mallya RK, Pepys MB, Schnebli HP. Quantitation of human leukocyte elastase, cathepsin G, alpha-2-macroglobulin and alpha-1-proteinase inhibitor in osteoarthrosis and rheumatoid arthritis synovial fluids. Adv Exp Med Biol. 1984;167:345–353. [PubMed]
  • Mochan E, Keler T. Plasmin degradation of cartilage proteoglycan. Biochim Biophys Acta. 1984 Aug 21;800(3):312–315. [PubMed]
  • Gormsen J, Andersen RB, Feddersen C. Fibrinogen-fibrin breakdown products in pathologic synovial fluids. An immunologic study. Arthritis Rheum. 1971 Jul-Aug;14(4):503–512. [PubMed]
  • Weinberg JB, Pippen AM, Greenberg CS. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991 Aug;34(8):996–1005. [PubMed]
  • Clemmensen I, Hølund B, Andersen RB. Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid. Arthritis Rheum. 1983 Apr;26(4):479–485. [PubMed]
  • Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med. 1992 Mar 19;326(12):800–806. [PubMed]
  • Altieri DC, Edgington TS. Sequential receptor cascade for coagulation proteins on monocytes. Constitutive biosynthesis and functional prothrombinase activity of a membrane form of factor V/Va. J Biol Chem. 1989 Feb 15;264(5):2969–2972. [PubMed]
  • van Dam-Mieras MC, Muller AD, van Deijk WA, Hemker HC. Clotting factors secreted by monocytes and macrophages: analytical considerations. Thromb Res. 1985 Jan 1;37(1):9–19. [PubMed]
  • Bajzár L, Fredenburgh JC, Nesheim M. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem. 1990 Oct 5;265(28):16948–16954. [PubMed]
  • Nesheim ME, Katzmann JA, Tracy PB, Mann KG. Factor V. Methods Enzymol. 1981;80(Pt 100):249–274. [PubMed]
  • Castellino FJ, Powell JR. Human plasminogen. Methods Enzymol. 1981;80(Pt 100):365–378. [PubMed]
  • Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem. 1977 Aug 15;78(1):19–26. [PubMed]
  • Krishnaswamy S, Church WR, Nesheim ME, Mann KG. Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem. 1987 Mar 5;262(7):3291–3299. [PubMed]
  • Lundblad RL, Kingdon HS, Mann KG. Thrombin. Methods Enzymol. 1976;45:156–176. [PubMed]
  • Straughn W, 3rd, Wagner RH. A simple method for preparing fibrinogen. Thromb Diath Haemorrh. 1966 Jul 31;16(1):198–206. [PubMed]
  • Nesheim ME. A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin. J Biol Chem. 1983 Dec 10;258(23):14708–14717. [PubMed]
  • Bloom JW, Nesheim ME, Mann KG. Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry. 1979 Oct 2;18(20):4419–4425. [PubMed]
  • Herman JH, Greenblatt D, Khosla RC, Appel AM. Cytokine modulation of chondrocyte proteinase release. Arthritis Rheum. 1984 Jan;27(1):79–91. [PubMed]
  • Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta. 1986 Sep 4;883(2):173–177. [PubMed]
  • Scully MF, Toh CH, Hoogendoorn H, Manuel RP, Nesheim ME, Solymoss S, Giles AR. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost. 1993 May 3;69(5):448–453. [PubMed]
  • Schalkwijk J, Joosten LA, van den Berg WB, van de Putte LB. Degradation of cartilage proteoglycans by elastase is dependent on charge-mediated interactions. Rheumatol Int. 1988;8(1):27–33. [PubMed]
  • Mann KG, Elion J, Butkowski RJ, Downing M, Nesheim ME. Prothrombin. Methods Enzymol. 1981;80(Pt 100):286–302. [PubMed]
  • Harlan JM. Consequences of leukocyte-vessel wall interactions in inflammatory and immune reactions. Semin Thromb Hemost. 1987 Oct;13(4):434–444. [PubMed]
  • Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med. 1984 Jun 1;159(6):1653–1668. [PMC free article] [PubMed]
  • Bizios R, Lai L, Fenton JW, 2nd, Malik AB. Thrombin-induced chemotaxis and aggregation of neutrophils. J Cell Physiol. 1986 Sep;128(3):485–490. [PubMed]
  • Richardson DL, Pepper DS, Kay AB. Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol. 1976 Apr;32(4):507–513. [PubMed]
  • Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. [PMC free article] [PubMed]
  • Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA., Jr Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984 Aug 1;160(2):618–623. [PMC free article] [PubMed]
  • Gajdusek C, Carbon S, Ross R, Nawroth P, Stern D. Activation of coagulation releases endothelial cell mitogens. J Cell Biol. 1986 Aug;103(2):419–428. [PMC free article] [PubMed]
  • Carney DH, Redin W, McCroskey L. Role of high-affinity thrombin receptors in postclotting cellular effects of thrombin. Semin Thromb Hemost. 1992 Jan;18(1):91–103. [PubMed]
  • Martel-Pelletier J, Faure MP, McCollum R, Mineau F, Cloutier JM, Pelletier JP. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol. 1991 Dec;18(12):1863–1871. [PubMed]
  • Treadwell BV, Pavia M, Towle CA, Cooley VJ, Mankin HJ. Cartilage synthesizes the serine protease inhibitor PAI-1: support for the involvement of serine proteases in cartilage remodeling. J Orthop Res. 1991 May;9(3):309–316. [PubMed]
  • Richardson M, Hatton MW, Moore S. The plasma proteases, thrombin and plasmin, degrade the proteoglycan of rabbit aorta segments in vitro: an integrated ultrastructural and biochemical study. Clin Invest Med. 1988 Apr;11(2):139–150. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation